Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa. Margolin, E.; Burgers, W. A.; Sturrock, E. D.; Mendelson, M.; Chapman, R.; Douglass, N.; Williamson, A.; and Rybicki, E. P. Nature Reviews Microbiology, Nature Publishing Group, sep, 2020.
Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa [link]Paper  doi  abstract   bibtex   2 downloads  
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic, prompting unprecedented efforts to contain the virus. Many developed countries have implemented widespread testing and have rapidly mobilized research programmes to develop vaccines and therapeutics. However, these approaches may be impractical in Africa, where the infrastructure for testing is poorly developed and owing to the limited manufacturing capacity to produce pharmaceuticals. Furthermore, a large burden of HIV-1 and tuberculosis in Africa could exacerbate the severity of infection and may affect vaccine immunogenicity. This Review discusses global efforts to develop diagnostics, therapeutics and vaccines, with these considerations in mind. We also highlight vaccine and diagnostic production platforms that are being developed in Africa and that could be translated into clinical development through appropriate partnerships for manufacture. The COVID-19 pandemic has prompted unparalleled progress in the development of vaccines and therapeutics in many countries, but it has also highlighted the vulnerability of resource-limited countries in Africa. Margolin and colleagues review global efforts to develop SARS-CoV-2 diagnostics, therapeutics and vaccines, with a focus on the opportunities and challenges in Africa.
@article{Margolin2020,
abstract = {The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic, prompting unprecedented efforts to contain the virus. Many developed countries have implemented widespread testing and have rapidly mobilized research programmes to develop vaccines and therapeutics. However, these approaches may be impractical in Africa, where the infrastructure for testing is poorly developed and owing to the limited manufacturing capacity to produce pharmaceuticals. Furthermore, a large burden of HIV-1 and tuberculosis in Africa could exacerbate the severity of infection and may affect vaccine immunogenicity. This Review discusses global efforts to develop diagnostics, therapeutics and vaccines, with these considerations in mind. We also highlight vaccine and diagnostic production platforms that are being developed in Africa and that could be translated into clinical development through appropriate partnerships for manufacture. The COVID-19 pandemic has prompted unparalleled progress in the development of vaccines and therapeutics in many countries, but it has also highlighted the vulnerability of resource-limited countries in Africa. Margolin and colleagues review global efforts to develop SARS-CoV-2 diagnostics, therapeutics and vaccines, with a focus on the opportunities and challenges in Africa.},
author = {Margolin, Emmanuel and Burgers, Wendy A. and Sturrock, Edward D. and Mendelson, Marc and Chapman, Rosamund and Douglass, Nicola and Williamson, Anna-Lise and Rybicki, Edward P.},
doi = {10.1038/s41579-020-00441-3},
issn = {1740-1526},
journal = {Nature Reviews Microbiology},
keywords = {Infectious,Medical research,Vaccines,Viral infection,disease diagnostics,fund{\_}ack,review},
mendeley-tags = {fund{\_}ack,review},
month = {sep},
pages = {1--15},
publisher = {Nature Publishing Group},
title = {{Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa}},
url = {http://www.nature.com/articles/s41579-020-00441-3},
year = {2020}
}
Downloads: 2